Replies to post #100570 on Biotech Values

[DewDiligence]

USPTO will not appeal MDCO’s victory on the Angiomax patent extension:

http://finance.yahoo.com/news/The-Medicines-Company-iw-3076217221.html?x=0&.v=1

MDCO’s PR was issued after the market close, but the actual decision occurred earlier, as evidenced by the 1-day chart: